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1. Data {#sec1}
=======

We have previously described a rapid non-genomic anti-secretory effect of corticosteroids on airway Cl^-^ secretion via inhibition of basolateral membrane K^+^ channels \[[@bib1], [@bib2], [@bib3]\]. Here we present the original data underpinning these findings.

2. Experimental design, materials, and methods {#sec2}
==============================================

2.1. Expression of the KCNN4 protein in 16HBE14o^−^ airway epithelial cells {#sec2.1}
---------------------------------------------------------------------------

Western blot analysis was performed to determine expression of the KCNN4 channel in 16HBE14o^−^ cells. Primers specific for KCNN4 (GenBank accessionNo. [AF000972](ncbi-n:AF000972){#intref0010}) were designed using the Primer 3 software ([Table 1](#tbl1){ref-type="table"}). A PCR product of the expected size was generated from complimentary DNA extracted from 16HBE14o^−^ cells ([Fig. 1](#fig1){ref-type="fig"}). The T84 cell line was used as a positive control. As illustrated in [Fig. 2](#fig2){ref-type="fig"}, an anti-KCNN4 antibody recognized prominent bands with the molecular masses of 46 kDa.Table 1First-strand cDNA was subjected to PCR amplification using primers designed with the Primer 3 PCR primer design program (Whitehead Institute for Biomedical Research).Table 1ProteinPrimer Sequence 5′ → 3′Product size bpKCNN4 (F)GCCGTGCGTGCAGGATTTAGG403KCNN4 (R)GCCCGGCACCACGTCACCATAGAPDH (F)CATTGGGGGTAGGAACACGGA373GAPDH(R)GCCAAAAGGGTCATCATCTCCGFig. 1**Semi-quantitative RT-PCR analysis of KCNN4 expression in 16HBE14o**^**−**^**cells.** Total RNA was isolated from 16HBE14o^−^ cells using RNA easy kit (Qiagen). cDNA was reverse transcribed using poly dT primers and ImProm*™ Reverse Transcriptase System* (Promega, USA) and 1 μl of this reaction was directly amplified using GoTaq® Green Master Mix. (Promega, USA) using specific primers for human KCNN4 isoform and synthesised by MWG Biotech (Germany). The PCR reaction produced DNA fragments at the expected length for KCNN4 in T84 and 16HBE14o^−^ cells. GAPDH (cDNA and GAPDH primer pairs) was used as a control and neg (negative control, primers pairs without cDNA).Fig. 1Fig. 2**KCNN4 protein expression in 16HBE14o**^**−**^**cells.** Western blot analysis of KCNN4 proteins in human bronchial epithelial cells. Total protein (100 μg/lane) was transferred to nitrocellulose membrane after fractionating by SDS-PAGE and blotted with anti-KCNN4. Bands at 46 kDa corresponding to KCNN4 were detected. β-actin was used as a control to estimate protein loading. Values represent mean ± SEM, n = 3; n.s. denotes values were not significant between T84 and 16HBE14o^−^ samples. Statistical analysis was performed using the Student\'s paired *t*-test.Fig. 2

2.2. Membrane expression of KCNN4 in 16HBE14o^−^ cells {#sec2.2}
------------------------------------------------------

Biotinylation experiments were performed to investigate the effect of dexamethasone on the expression and membrane localization of KCNN4 channels ([Fig. 3](#fig3){ref-type="fig"}). The presence of KCNN4 at the basolateral membrane was confirmed by cell surface biotinylation. However, no change in surface expression of KCNN4 following dexamethasone (15mins, 1 nM) or vehicle (15mins, methanol, 0.001% v/v) treatment was observed.Fig. 3**KCNN4 channels are present at the membrane in 16HBE14o**^**−**^**cells.** Representative Western blot of biotin-labelled cell surface KCNN4 protein. Dexamethasone (1nM) or vehicle (methanol, 0.001% v/v) was added to 16HBE14o^−^ cells for 15 mins. Barchart summary for the effect of dexamethasone on cell surface biotinylation in 16HBE14o^−^ cells. Values are mean ± SEM, n = 3, n.s. denotes values are not significant. Statistical analysis was performed by one-way ANOVA followed by Tukey\'s multiple comparison tests.Fig. 3

2.3. Expression of KCNQ1 channels in 16HBE14o^−^ airway epithelial cells {#sec2.3}
------------------------------------------------------------------------

Semi-quantitative RT-PCR was carried out to determine expression of KCNQ1. Different primer pairs, designed to specifically amplify human KCNQ1 was used to generate PCR products from cDNAs of 16HBE14o^−^ cells ([Table 2](#tbl2){ref-type="table"}). Human KCNQ1 (hKCNQ1) cloned into pTLN6, was kindly provided by Prof. Thomas Jentsch (Leibniz-Institute for Molecular Pharmacology, Berlin, Germany), and was used as a positive control for KCNQ1 expression. Agarose gels showing RT-PCR products amplified from 16HBE14o^−^ cDNA with PCR primer pairs for hKCNQ1. [Fig. 4](#fig4){ref-type="fig"} shows that the hKCNQ1 product was detected in 16HBE14o^−^ cells. Western blot analysis was performed to determine expression of the KCNQ1 channel and its regulatory subunit KCNE3 in 16HBE14o^−^ cells ([Fig. 5](#fig5){ref-type="fig"}). As illustrated, anti-KCNQ1 and anti-KCNE3 antibodies recognized prominent bands with the molecular masses of 37 kDa and 27 kDa respectively. The T84 cell line was used as a positive control as these cells are known to express KCNQ1 protein. These data confirm that the cAMP-dependent KCNQ1 channels and their KCNE3 regulatory subunit are expressed in 16HBE14o^−^ cells.Table 2Oligonucleotide sequences of human KCNQ1 and GAPDH primers used for RT-PCR. HKCNQ1primers were designed using the Primer 3 program.Table 2ProteinPrimer Sequence 5′ → 3′Product size bpKCNQ1 (F)ATCTGCGTAGCTGCCAAAC272KCNQ1 (R)TAGCTCAAACCGTCGATGCGGAPDH (F)CATTGGGGGTAGGAACACGGA373GAPDH(R)GCCAAAAGGGTCATCATCTCCGFig. 4**Expression of KCNQ1 channel in 16HBE14o**^**−**^**cells.** Semi-quantitative RT-PCR analysis of KCNQ1 expression in 16HBE14o^−^ cells was amplified using specific primers for human KCNQ1, pRTLN-KCNQ1 (used as a positive control), ctl (negative control using hKCNQ1 primer pairs without cDNA), GAPDH (cDNA and GAPDH primer pairs) was used as a control.Fig. 4Fig. 5**KCNQ1 and KCNE3 are expressed in 16HBE14o**^**−**^**cells**. Western blot analysis of the KCNQ1 and KCNE3 proteins in 16HBE14o^−^ cells. Total protein (100 μg/lane) was transferred to nitrocellulose membrane after fractioning by SDS-PAGE and blotted with anti-KCNQ1 or anti-KCNE3. β-actin was used as a control to estimate protein loading.Fig. 5

2.4. Expression of K~ATP~ channels in 16HBE14o^−^ epithelial cells {#sec2.4}
------------------------------------------------------------------

The molecular identity of the lung K~ATP~ channel subunits was investigated in the 16HBE14o^−^ cells. Different primer pairs, designed to specifically amplify human Kir 6.1, Kir 6.2, SUR 1 and SUR 2A ([Table 3](#tbl3){ref-type="table"}) were used to generate PCR products from cDNAs of 16HBE14o^−^ cells. The Kir 6.1 and Kir 6.2 primer pairs amplified bp products, respectively ([Fig. 6](#fig6){ref-type="fig"}). In addition, the SUR 1 primer pairs amplified a 340 bp product. No product could be detected with primers for SUR2A. These results suggest that the K~ATP~ channels in 16HBE14o^−^ cells could be formed from Kir 6.1, Kir 6.2 and SUR2A subunits. The sulfonylurea receptors SUR 2A and subunits Kir 6.1 and Kir 6.2 were found to be expressed in the 16HBE14o^−^ cell line.Table 3Oligonucleotide sequences of primers used for K~ATP~ channel RT-PCR.Table 3ProteinPrimer Sequence 5′ → 3′Product size bpKir 6.1(F)GCCAGAAAGAGTATCATCCCGGAG352Kir 6.1(R)CATTCCACTTTTCTCCATGTAAGCKir 6.2 (F)ATGCTGTCCCGCAAGGGCATC360Kir 6.2 (R)TAGTCACTTGGACCTCAATGGAGSUR1 (F)CGATGCCATCATCACAGAAG340SUR1(R)CTGAGCAGCTTCTCTGGCTTSUR2A (F)GCTGAAGAATATGGTCAAATCTC355SUR2A (R)TGGAGTGTCATATTCTAAAATAGAPDH (R)GCCAAAAGGGTCATCATCTCCG373GAPDH (F)CATTGGGGGTAGGAACACGGAFig. 6Agarose gel showing RT-PCR products amplified from 16HBE14o^−^ cDNA with PCR primer pairs for Kir6.1, Kir 6.2, SUR1, SUR2A and GAPDH. Semi-quantitative RT-PCR analysis of Kir6.1, Kir 6.2, SUR1, SUR2A and GAPDH expression in human bronchial epithelial cells was amplified using specific human primers.Fig. 6

2.5. Cell surface expression of KCNQ1 {#sec2.5}
-------------------------------------

Biotinylation experiments were performed to investigate the effect of dexamethasone on the localization of the KCNQ1 channel. The presence of KCNQ1 at the membrane was confirmed by cell surface biotinylation ([Fig. 7](#fig7){ref-type="fig"}). There was no change in surface expression of KCNQ1 following dexamethasone (1 nM) or vehicle (0.001% methanol) treatment indicating that dexamethasone does not change the cellular localization or expression of the KCNQ1 channel.Fig. 7**The KCNQ1 channel expression at the basolateral membrane in 16HBE14o**^**−**^**cells.** Representative Western blot of labelling cell surface KCNN4 proteins with Biotin-LC-hydrazide. Dexamethasone (1nM) and vehicle control (methanol, 0.001% v/v) were added to 16HBE14o^−^ cells for 15 mins. Bar chart summary for the effect of dexamethasone on cell surface biotinylation in 16HBE14o^−^ cells. Values are mean ± SEM; n.s. denotes that values were not significant compared to control values. Statistical analysis was performed by one-way ANOVA followed by Tukey\'s multiple comparison tests.Fig. 7

2.6. Effects of dexamethasone on expression and activation of PKC isoforms in human bronchial epithelial cells {#sec2.6}
--------------------------------------------------------------------------------------------------------------

Candidate protein kinase C isoforms of the cPKC and the nPKC groups were investigated in mediating the rapid anti-secretory responses to dexamethasone. Primers specific for PKCα, PKCδ, PKCε and PKD were designed using the Primer 3 program. PCR products of the expected size were generated from cDNA extracted from 16HBE14o^−^ cells ([Table 4](#tbl4){ref-type="table"}, [Fig. 8](#fig8){ref-type="fig"}).Table 4List of primers for PKC isoforms and GAPDH.Table 4ProteinPrimer Sequence 5′ → 3′Product size bpPKCα (F)CGAGGAAGGAAACATGGAACTCAG193PKCα (R)TTTCCACTACGAACGGCTCTCCPKCδ (F)GCATCGCCTTCAACTCCTATGAGCT249PKCδ (R)ACACACCCACGGTCACCTCAGAPKCε (F)TCAATGGCCTTCTTAAGATCAAAA388PKCε (R)CCTGAGAGATCGATGATCACATACPKD (F)TATCCAGGAAGGCGATCTTATTGAAGTG236PKD (R)GCCTCACACCGCTGCAATTGTTGGAPDH (F)CATTGGGGGTAGGAACACGGA373GAPDH (R)GCCAAAAGGGTCATCATCTCCGFig. 8**Semi-quantitative RT-PCR analysis of PKC isoforms in human bronchial epithelial cells.** Total RNA was isolated from 16HBE14o^−^ cells using RNA easy kit (Qiagen). cDNA was reverse transcribed using poly dT primers and ImProm*™ Reverse Transcriptase System* (Promega, USA) and 1 μl of this reaction was directly amplified using GoTaq® Green Master Mix. (Promega, USA) using specific primers for human PKC isoforms and PKD ([Table 3](#tbl3){ref-type="table"}) and synthesised by MWG Biotech (Germany). The PCR reaction produced DNA fragments at the expected length for PKCα, PKCδ, PKCε and PKCμ (PKD1). GAPDH (+) (cDNA and GAPDH primer pairs) was used as a control. Image representative of three independent experiments.Fig. 8

2.7. Expression of PKC isoforms in human bronchial epithelial cells {#sec2.7}
-------------------------------------------------------------------

The results obtained from RT-PCR analysis were confirmed by western blotting. Western blots were performed on three independently derived cell lysates to establish PKC isoform expression. As a positive control lysates from MCF-7 breast cancer cell line was used. Western blot analysis revealed expression of these selected isoforms in 16HBE14o^−^ cells. An equivalent amount of protein (50 μg) was loaded in each track and equal loading of samples was confirmed by probing the same blot with β-actin monoclonal antibody.

Immunoblots using antibodies for individual isoforms of PKC were performed: PKCα ([Fig. 9Α](#fig9){ref-type="fig"}), PKCδ ([Fig. 9Β](#fig9){ref-type="fig"}), PKCε ([Fig. 9](#fig9){ref-type="fig"}C) and PKD ([Fig. 9](#fig9){ref-type="fig"}D) in 16HBE14o^−^ cells and MCF-7 cells. Western blot analysis revealed the expression of the classical isoform PKCα (80 kDa), the novel isoforms PKCδ (78 kDa) and PKCε (95 kDa) and also expression of PKD (115 kDa). PKCα and PKD1 were expressed in equal quantities in 16HBE14o^−^ cells compared to MCF-7 cells (positive control). PKCδ and PKCε were significantly (\*\*p \< 0.001, \*p \< 0.01) respectively, less expressed in 16HBE14o^−^ cells compared to MCF-7 control. This reflected non-uniform expression of PKC isoform levels (PKCα \> PKD1 \> PKCε \> PKCδ levels of expression).Fig. 9**PKCα, PKCδ, PKCε and PKD1 (PKCμ) are expressed in 16HBE14o**^**−**^**cells.** Representative Western blot analysis of PKC subunits: PKCα (Α), PKCδ (Β), PKCε (C) and PKD1 (D) in cellular extracts of 16HBE14o^−^ and MCF-7 cells. Total protein (50 μg/lane) was transferred to nitrocellulose membranes after fractionating by SDS-PAGE and blotted with anti-PKC antibodies. β-actin (42 kDa) was used as an internal control to estimate protein loading. The graphs represent densitometric analysis of PKC expression. Values are given as reflective PKC expression in 16HBE14o^−^ cell lysates compared to MCF- 7. Values are displayed as mean ± SEM (n = 3). \*\* Denotes p \< 0.001, \* denotes p \< 0.01, n.s. denotes not significant (p \> 0.05) between PKC isoform in MCF-7 and 16HBE14o^−^. Statistical analysis was performed using the Students paired *t*-test.Fig. 9

2.8. Effect of dexamethasone on PKCα, PKCδ and PKCε activity in 16HBE14o^−^ cells {#sec2.8}
---------------------------------------------------------------------------------

The levels of PKC isoform activation can be observed through changes in phosphorylation states at key amino acid residues. For PKCα activation Ser657 autophosphorylation in the hydrophobic *C*-terminal is required for catalytic activation and stabilisation of the protein upon translocation to the plasma membrane. PKCδ activity was assessed using an antibody to PKCδ phosphorylated at Ser643. PKCδ autophosphorylates at Ser643 in the turn motif after initial phosphorylation at Thr505 by PDK-1 in the activation loop. PKCε activation requires phosphorylation at three sites (1): Thr666 in the activation loop (2), Ser729 in the *C*-terminal hydrophobic region and (3) autophosphorylation at Thr710. The level of phosphorylation at these residues can be used as a measure of catalytic activity of the kinase isoforms. By employing antibodies specific to the phosphorylated form of PKCs, activation was monitored in response to dexamethasone by Western blot analysis.

PKCα activation was assessed by probing with a specific antibody to phosphorylation at Ser 657. Dexamethasone treatment produced a biphasic activation of PKCα at 2 and 10 mins ([Fig. 10](#fig10){ref-type="fig"}, [Table 5](#tbl5){ref-type="table"}). PKCδ activity was measured using a specific antibody to phosphorylation at Ser643. Dexamethasone treatment had no effect on PKCδ phosphorylation levels ([Fig. 11](#fig11){ref-type="fig"}, [Table 6](#tbl6){ref-type="table"}). PKCε activity was measured using a specific antibody to phosphorylation at Ser 729. Dexamethasone treatment had no effect on PKCε phosphorylation levels ([Fig. 12](#fig12){ref-type="fig"}, [Table 6](#tbl6){ref-type="table"}). Bombesin was used as a positive control for PKC activation. Stripping the blot and reprobing with β-actin showed equal loading of all lanes. These results show that dexamethasone selectively activates classical PKCα and does not rapidly activate the novel PKC isoforms: PKCδ and PKCε.Fig. 10**PKCα is rapidly activated in response to dexamethasone in 16HBE14o**^**−**^**cells.** Representative Western blot analysis of phospho-PKCα in cellular extracts of 16HBE14o^−^. The activation of PKCα by dexamethasone was monitored using antibodies specific to the phosphorylated form of PKCα (Ser 657). β-actin (42 kDa) was used as an internal control to estimate protein loading. The graph represents densitometric analysis at specific time points of dexamethasone treatment. Values are given as fold changes in PKCα activation of 16HBE14o^−^ cell lysates. Values are displayed as mean ± SEM (n = 4). \*\* Denotes significance: p \< 0.001, \* denotes p \< 0.01 between control and treated values. Statistical analysis was performed using one-way ANOVA followed by Tukey\'s multiple comparison tests.Fig. 10Table 5Summary of the fold increase in PKCα activity induced by dexamethasone.Table 5TreatmentPKCα activation (phosphorylation at Ser 657)Lysate control1 ± 0Dexamethasone (1nM, 2 min)5.12 ± 1.9Dexamethasone (1nM, 5 min)1.95 ± 0.39Dexamethasone (1nM, 10 min)3.84 ± 0.39Dexamethasone (1nM, 15 min)2.05 ± 0.56Methanol (0.001% v/v, 2 min)1.79 ± 0.33Methanol (0.001% v/v, 5 min)1.81 ± 0.20Methanol (0.001% v/v, 10 min)1.40 ± 0.16Methanol (0.001% v/v, 15 min)1.05 ± 0.34Fig. 11**Dexamethasone does not activate the nPKC isoform: PKCδ in 16HBE14o**^**−**^**cells.** Representative Western blot analysis of phospho-PKCδ in cellular extracts of 16HBE14o^−^. Using antibodies specific to the phosphorylated form of PKCδ (Ser 643), the activation by dexamethasone was monitored by Western blot analysis. β-actin (42 kDa) was used as an internal control to estimate protein loading. The graph represents densitometric analysis at specific time points of dexamethasone treatment. Bombesin (BOM) was used as a positive control for PKCδ activity. Values are given as fold changes in PKCδ activation of 16HBE14o^−^ cell lysates. Values are displayed as mean ± SEM (n = 4); n.s. denotes no significance between control and treated values. Statistical analysis was performed using one-way ANOVA followed by Tukey\'s multiple comparison tests.Fig. 11Table 6Summary of the fold increases in PKCδ activity.Table 6TreatmentPKCδ activation (phosphorylation at Ser 643)Lysate control1.1 ± 0.27Dexamethasone (1nM, 2 min)1.46 ± 0.36Dexamethasone (1nM, 5 min)1.69 ± 0.27Dexamethasone (1nM, 10 min)1.67 ± 0.32Dexamethasone (1nM, 15 min)2.09 ± 0.32Methanol (0.001% v/v, 2 min)1.74 ± 0.26Methanol (0.001% v/v, 5 min)1.89 ± 0.40Methanol (0.001% v/v, 10 min)1.78 ± 0.46Methanol (0.001% v/v, 15 min)1.65 ± 0.31Control1.43 ± 0.28Bombesin4.03 ± 0.12Fig. 12**Dexamethasone does not activate the nPKC isoform: PKCε in 16HBE14o**^**−**^**cells.** Representative Western blot analysis of phospho- PKCε in cellular extracts of 16HBE14o^−^. Using antibodies specific to the phosphorylated form of PKCε (Ser 729), the activation by dexamethasone was monitored by Western blot analysis. β-actin (42 kDa) was used as an internal control to estimate protein loading. The graph represents densitometric analysis at specific time points of dexamethasone treatment. Values are given as fold changes in PKCε activation of 16HBE14o^−^ cell lysates as detailed in [Table 7](#tbl7){ref-type="table"}. Bombesin (BOM) was used as a positive control for PKCε activity. Values are displayed as mean ± SEM (n = 3); n.s. denotes no significance between control and treated values. Statistical analysis was performed using one-way ANOVA followed by Tukey\'s multiple comparison tests.Fig. 12Table 7Summary of the fold increase in PKCε activity induced by dexamethasone.Table 7TreatmentPKCε activation (phosphorylation at Ser 729)Lysate control1 ± 0Dexamethasone (1nM, 2 min)1.5 ± 0.31Dexamethasone (1nM, min)1.45 ± 0.24Dexamethasone (1nM, 10 min)1.27 ± 0.15Dexamethasone (1nM, 15 min)1.26 ± 0.13Methanol (0.001% v/v, 2 min)1.22 ± 0.11Methanol (0.001% v/v, 5 min)1.25 ± 0.12Methanol (0.001% v/v, 10 min)1.29 ± 0.05Methanol (0.001% v/v, 15 min)1.22 ± 0.11Bombesin3.54 ± 0.24Control1.71 ± 0.17

2.9. Expression of cAMP-adenylyl cyclase -PKA signaling pathway in 16HBE14o^−^ cells {#sec2.9}
------------------------------------------------------------------------------------

Adenylyl cyclase (AC) expression was determined in 16HBE14o^−^ cells. Because of the unavailability of satisfactory antibodies for most of the AC isoforms, the expression of AC isoforms was investigated by RT- PCR ([Table 8](#tbl8){ref-type="table"}). As shown in [Fig. 13](#fig13){ref-type="fig"}, the AC isoforms AC3, AC4, AC6 and AC7 were found to be expressed in 16HBE14o^−^ cells.Table 8List of primers for human adenylyl cyclase isoforms AC1-9 and GAPDH.Table 8ProteinPrimer Sequence 5′ → 3′Product size bpGenBank Accession No.AC1 (F)CATGACCTGCGAGGACGAT446[L05500](ncbi-n:L05500){#intref0015}AC1 (R)ACAGGAGACTGCGAATCTGAAAC2 (F)GGGGCTGCGTTTCTCT369[X74210](ncbi-n:X74210){#intref0020}AC2 (R)CAGGAACACGGAACAGGATAAC3 (F)CACGGGACCCAGCAAT263[NM_004036](ncbi-n:NM_004036){#intref0025}AC3 (R)GCTCTAAGGCCACCATAGGTAAC4 (F)TGAACCATGGACCCGTAG287[AF088070](ncbi-n:AF088070){#intref0030}AC4 (R)GCGAGTGCAATCTCAGCAC5 (F)ACCAAGGCTACACTCAACTAC163[U65473](ncbi-n:U65473){#intref0035}AC5 (R)GGTTCATCTTGGCGATCAAC6 (F)GGCATTGATGATTCCAGCAAAGAC380[AB007882](ncbi-n:AB007882){#intref0040}AC6 (R)TGCAGGGCCTTAGGGAACAGAAC7 (F)TTAGCACATGATGAAAACAGACTT359[NM_001114](ncbi-n:NM_001114){#intref0045}AC7 (R)CACTGGAGGGAAGAGATTTATGAC8 (F)CGGGATTTGGAACGCCTCTA543[NM_001115](ncbi-n:NM_001115){#intref0050}AC8 (R)CCGGTCTGACAGGTAACTGATAAAC9 (F)CACCGCAAAATACTTAGATGACG497[NM_001116](ncbi-n:NM_001116){#intref0055}AC9 (R)CCTTCTCCTGCAAGATCTCACACGAPDH (F)CATTGGGGGTAGGAACACGGA373XO2231GAPDH (R)GCCAAAAGGGTCATCATCTCCGFig. 13**Semi-quantitative RT-PCR analysis of adenylyl cyclase isoforms AC1- 9 in human bronchial epithelial cells**. Total RNA was isolated from 16HBE14o^−^ cells using RNA easy kit (Qiagen). cDNA was reverse transcribed using poly dT primers and ImProm*™ Reverse Transcriptase System* (Promega, USA) and 1 μl of this reaction was directly amplified using GoTaq® Green Master Mix. (Promega, USA) using specific primers for human AC isoforms (Xu, D, Isaaca, C (2001)) ([Table 3](#tbl3){ref-type="table"}) and synthesised by MWG Biotech (Germany). The PCR reaction produced DNA fragments at the expected length for AC 3, 4, 6 and 7. (+) denotes GAPDH and (−) denotes negative control. Figure representative of three independent experiments.Fig. 13

2.10. Expression of PKA regulatory and catalytic subunits in human bronchial epithelial cells {#sec2.10}
---------------------------------------------------------------------------------------------

Since AC isoforms are expressed in 16HBE14o^−^ cells, it was of interest to investigate the expression levels of the catalytic and regulatory subunits of PKA in 16HBE14o^−^ cells. The PKA isoform I (PKA~I~) the soluble cytosolic isoform, was investigated in cellular extracts in this study, as distinct from isoform II which is membrane bound. Total untreated cellular lysates of 16HBE14o^−^ cells were prepared and subjected to western blot analysis by probing with specific antibodies to endogenous levels of PKA regulatory (PKA~RI~) and catalytic (PKA~CI~) subunits. As shown in [Fig. 14](#fig14){ref-type="fig"}, 16HBE14o^−^ cells express equal levels of both PKA~RI~ and PKA~CI~ subunits compared with MCF-7 cells used as a positive control. Expression differences were normalized for loading by probing for total β-actin levels.Fig. 14**PKA**~**CI**~**and PKA**~**RI**~**are expressed in 16HBE14o**^**−**^**cells. A:** The graph represents densitometric analysis of PKA expression. Values are given as fold differences in PKA expression between MCF-7 and 16HBE14o^−^ cell lysates. Values are displayed as mean ± SEM (n = 3). n.s. denotes not significant (P \> 0.05) between MCF-7 and 16HBE14o^−^ cells in PKA~CI~ and PKA~RI~ expression. Statistical analysis was performed by the Student\'s paired *t*-test for three independent experiments. **B:** Representative Western blot analysis of PKA~CI~ and PKA~RI~ subunit in cellular extracts of 16HBE14o^−^ and MCF-7 cells. Total protein (50 μg/lane) was transferred to nitrocellulose membranes after fractionating by SDS-PAGE and blotted with anti-PKA~RI~ (48kDa) and anti-PKA~CI~ (40kDa). β-actin (42 kDa) was used as an internal control to estimate protein loading.Fig. 14

2.11. Dexamethasone effects on cAMP-dependent protein kinase A activity {#sec2.11}
-----------------------------------------------------------------------

The cAMP-adenylyl-PKA signaling pathway is clearly expressed in 16HBE14o^−^ cells. We therefore examined the effects of dexamethasone on PKA activity. To determine the time course of dexamethasone activation of PKA in 16HBE14o^−^ cells, serum starved cells were exposed to dexamethasone (1 nM) or equivalent vehicle (methanol, 0.001% v/v) for the duration of 2, 5 and 10 mins. PKA activity was rapidly and dramatically upregulated after 5 mins in response to dexamethasone (1 nM) treatment and returned to basal levels after 10 mins ([Fig. 15](#fig15){ref-type="fig"}). The effect was comparable to forskolin (20 μM) a well-known activator of AC. A summary of the fold increases in PKA activity for each treatment is shown in [Table 9](#tbl9){ref-type="table"}.Fig. 15**PKA is rapidly activated in response to dexamethasone in 16HBE14o**^**−**^**cells. A:** The graph represents densitometric analysis at specific time points of dexamethasone treatment. Values are given as fold changes in PKA phosphorylation of the F-Kemptide PepTag for 16HBE14o^−^ cell lysates. Values are displayed as mean ± SEM (n = 6). \*\* Denotes significance (p \< 0.001) between control and treated values. Statistical analysis was performed by one-way ANOVA followed by Tukey\'s multiple comparison tests. **B:** Representative image of PKA activation of an F-Kemptide PepTag in cellular extracts from 16HBE14o^−^ cells. PKA activity phosphorylated the F-Kemptide PepTag peptide changing its net charge from +1 to −1. This allows the phosphorylated and nonphosphorylated forms of the substrate to be rapidly separated on agarose gel. Lane 1, lysate control, Lane 2, forskolin (20 μM/5 min), Lane 3, dexamethasone (1 nM, 2 min), Lane 4, dexamethasone, (1 nM, 5 min), Lane 5, dexamethasone (1 nM, 10 min), Lane 6, vehicle control (methanol 0.001% v/v/2 min), Lane 7, vehicle control (methanol 0.001% v/v, 5 min), Lane 8, vehicle control (methanol 0.001% v/v, 10 min).Fig. 15Table 9Summary of the fold increases in PKA activity following dexamethasone treatment.Table 9TreatmentFold increase in PKA activityForskolin (20 μM, 5 min)3.4 ± 0.81Dexamethasone (1 nM, 0 min)1 ± 0Dexamethasone (1 nM, 2 min)1.03 ± 0.05Dexamethasone (1 nM, 5 min)2.6 ± 0.35Dexamethasone (1 nM, 10 min)0.93 ± 0.17Methanol (0.001% v/v, 2 min)0.87 ± 0.25Methanol (0.001% v/v, 5 min)1.04 ± 0.05Methanol (0.001% v/v, 10 min)1.05 ± 0.08

2.12. PKA and cAMP effects on cAMP-dependent protein kinase activity {#sec2.12}
--------------------------------------------------------------------

The adenylyl cyclase activator, forskolin, and the PKA antagonist, R~p~-cAMP\[S\], were used as positive and negative controls for PKA stimulation, respectively. Dexamethasone increased PKA activity and this effect was inhibited by R~p~-cAMP\[S\] ([Fig. 16](#fig16){ref-type="fig"}). The effect was comparable to forskolin, a known activator of adenylyl cyclase. [Table 10](#tbl10){ref-type="table"} shows a summary of fold increases in PKA activity.Fig. 16**Dexamethasone effect on PKA activity in 16HBE14o**^**−**^**cells**. **A:** The graph represents densitometric analysis of treatments. Values are given as fold changes in PKA activity, measured as phosphorylation of the F-Kemptide PepTag for 16HBE14o^−^ cell lysates. Values are displayed as mean ± SEM (n = 4). \*\* Denotes significance (p \< 0.001) between dexamethasone and dexamethasone + Rp-cAMP\[S\] treated values. Statistical analysis was performed by one-way ANOVA followed by Tukey\'s multiple comparison tests. **B:** UV-illuminated agarose gel of the products of reactions run with F-Kemptide and 16HBE14o^−^ homogenate. PKA activity phosphorylated the F-Kemptide PepTag peptide changing its net charge from +1 to −1. This allows the phosphorylated and nonphosphorylated forms of the substrate to be rapidly separated on agarose gel. Lane 1, forskolin (20 μM/5 min), Lane 2, lysate control, Lane 3, vehicle control (methanol, 0.001% v/v, 5 min), Lane 4, Rp-cAMP \[S\] (prior treatment 20 μM/40 min) and dexamethasone (1 nM, 5 min), Lane 5, dexamethasone (1 nM, 5 min) (Verriere et al., 2005).Fig. 16Table 10Summary of the fold increases in PKA activity.Table 10TreatmentFold increase in PKA activityForskolin (20 μM, 5 min)2.39 ± 0.30Dexamethasone (1 nM, 5 min)2.97 ± 0.07Dexamethasone (1 nM, 5 min) + Rp-cAMP\[S\] (20 μM, prior treatment 40 min)1.75 ± 0.13Lysate control1.1 ± 0.07Methanol (0.001% v/v, 5 min)0.92 ± 0.51

2.13. Dexamethasone induces rapid non-genomic PKA activation {#sec2.13}
------------------------------------------------------------

The rapid time course (5 minutes) of the dexamethasone effect on PKA activity suggests that this response does not involve a classical genomic mechanism. In order to verify this hypothesis we investigated the dexamethasone response in the presence of cycloheximide, an inhibitor of mRNA translation. Dexamethasone (1 nM) stimulated a 2.62 ± 0.29 -fold increase in total PKA activity in 16HBE14o^−^ cells after 5min ([Fig. 17](#fig17){ref-type="fig"}). This increase was not inhibited by preincubation with cycloheximide (1 μM) for 1 hour. The vehicle control and cycloheximide alone did not stimulate a significant change in PKA activity relative to untreated control. [Table 11](#tbl11){ref-type="table"} shows a summary for the fold changes in PKA activity. This result indicates that the dexamethasone induced increase in PKA activity observed after 5 min treatment is not dependent on changes in gene translation.Fig. 17**Dexamethasone induces PKA activity independent of translation. A:** The graph represents densitometric analysis of treatments. Values are given as fold changes in PKA activity measured as phosphorylation of the F-Kemptide PepTag for 16HBE14o^−^ cell lysates. Values are displayed as mean ± SEM (n = 4), n.s. denotes not significance (p \> 0.05) between dexamethasone and dexamethasone and inhibitor treated values. Statistical analysis was performed by one-way ANOVA followed by Tukey\'s multiple comparison tests. **B:** UV-illuminated agarose gel of the products of reactions run with F-Kemptide and 16HBE14o^−^ homogenate. Lane 1, dexamethasone (1 nM, 5 min) Lane 2, cycloheximide (prior treatment 1 μM/60 min) and dexamethasone, (1 nM, 5 min) Lane 3, vehicle control (methanol, 0.001% v/v, 5 min), Lane 4, methanol, 0.001% v/v 5 min and cycloheximide.Fig. 17Table 11Summary of the fold increases in PKA activity.Table 11TreatmentFold increase in PKA activityDexamethasone (1nM, 5 min)2.62 ± 0.29Dexamethasone (1 nM, 5 min) + cycloheximide (1 μM, 60 min prior treatment)2.9 ± 0.27Methanol (0.001% v/v, 5 min)1.2 ± 0.26Methanol (0.001% v/v, 5 min) + cycloheximide\
(1 μM, 60 min prior treatment)1.77 ± 0.21

2.14. Role of MR and GR in dexamethasone PKA response? - Effect of the classic glucocorticoid antagonist, RU486 and the mineralocorticoid antagonist, spironolactone on dexamethasone-induced PKA activity {#sec2.14}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In order to investigate the receptor involved in the rapid response to dexamethasone, RU486 and spironolactone were used as antagonists of the GR and the MR, respectively. In control experiments the receptor antagonists did not affect basal PKA activity. Furthermore, neither RU486 nor spironolactone treatment significantly affected the dexamethasone induced PKA activation in 16HBE14o^−^ cells ([Fig. 18](#fig18){ref-type="fig"}, [Table 12](#tbl12){ref-type="table"}). Taken together, these data indicate the rapid effect of dexamethasone on PKA activity in human airway epithelial cells is a non-genomic response that does not involve the nuclear GR or MR receptors.Fig. 18**Dexamethasone induces PKA activity independent of the classical GR and MR receptor antagonists. A:** The graph represents densitometric analysis at specific time points of dexamethasone treatment. Values are given as fold changes in PKA activity measured as phosphorylation of the F-Kemptide PepTag for 16HBE14o^−^ cell lysates. Values are displayed as mean ± SEM (n = 4). n.s. denotes not significant between dexamethasone and dexamethasone and inhibitor treated values. Statistical analysis was performed by one-way ANOVA followed by Tukey\'s multiple comparison tests. **B:** UV-illuminated agarose gel of the products of reactions run with F-Kemptide and 16HBE14o^−^ homogenate. Lane 1, lysate control, Lane 2, dexamethasone (1 nM, 5 min), Lane 3, RU486 (prior treatment 1 μM/30 min) and dexamethasone (1 nM, 5 min), Lane 4, vehicle control (methanol, 0.001% v/v, 5 min), Lane 5, RU486 + vehicle control (methanol 0.001% v/v, 5 min), Lane 6, dexamethasone (1 nM, 5 min), Lane 7, spironolactone (prior treatment 10 μM/30 min) and dexamethasone, (1 nM, 5 min), Lane 8, spironolactone + vehicle control (methanol 0.001% v/v, 5 min).Fig. 18Table 12Summary of the fold increases in PKA activity.Table 12TreatmentFold increase in PKA activityLysate control1.0 ± 0Dexamethasone (1nM, 5 min)2.35 ± 0.17Dexamethasone (1 nM, 5 min) + RU486 (1 μM, 30 min prior treatment)2.48 ± 0.20Methanol (0.001% v/v, 5 min)1.24 ± 0.16Methanol (0.001% v/v, 5 min) + RU486 (1 μM)1.52 ± 0.11Dexamethasone (1nM, 5 min)2.37 ± 0.25Dexamethasone + spironolactone (10 μM, 30 min prior treatment)2.37 ± 0.33Methanol (0.001% v/v, 5 min) + spironolactone (10 μM)1.49 ± 0.21

2.15. Role of pertussis toxin sensitive G protein-coupled receptors in the PKA response to dexamethasone {#sec2.15}
--------------------------------------------------------------------------------------------------------

The role of G protein-coupled receptors (GPCRs) in the rapid response to dexamethasone was investigated using pertussis toxin (PTX). As shown in [Fig. 19](#fig19){ref-type="fig"} and [Table 13](#tbl13){ref-type="table"}, PKA activity was up-regulated in less than 5 min by 40% over control (p \< 0.01) following 1 nM dexamethasone treatment. The G~i~ protein inhibitor, PTX (2 μg/l) significantly inhibited the activation of PKA by dexamethasone. The cells pretreated with PTX before dexamethasone did not show a significantly increased phosphorylation compared with untreated control cells (*p* \> 0.1). In contrast, the MEK 1 inhibitor, PD98059 (50 μM), had no significant effect on PKA activation by the steroid (p \> 0.1). In these experiments, the AC activator, forskolin, and the PKA antagonist, (*R*~p~)-cAMP, were used as positive and negative controls for PKA stimulation, respectively. The vehicle control (methanol 0.001% v/v) did not stimulate PKA activity. These data suggest a role for a PTX sensitive G protein-coupled receptor in the rapid PKA response to dexamethasone.Fig. 19**Role of pertussis toxin sensitive G Protein--coupled receptor in the dexamethasone-induced PKA activity. A:** The graph represents densitometric analysis at specific time points of dexamethasone treatment. Values are given as fold changes in PKA activity measured as phosphorylation of the F-Kemptide PepTag for 16HBE14o^−^ cell lysates. Values are displayed as mean ± SEM (n = 4). \*\* Denotes significance (p \< 0.001) between dexamethasone and dexamethasone + pertussis toxin treated values. Statistical analysis was performed by one-way ANOVA followed by Tukey\'s multiple comparison tests. **W** UV-illuminated agarose gel of the products of reactions run with F-Kemptide and 16HBE14o^−^ cell homogenate. PKA activity phosphorylated the PepTag peptide (F-Kemptide) changing its net charge from +1 to −1. *Lane 1*, forskolin (20 μM/5 min); *lane 2*, dexamethasone (1 nM/5 min); *lane 3*, PD98059 (prior treatment 50 μM/40 min) and dexamethasone (1 nM/5 min); *lane 4*, pertussis toxin (prior treatment 2 μg/l, 20 min) and dexamethasone (1 nM/5 min); *lane 5*, vehicle control (methanol 0.001% v/v), (Verriere et al., 2005).Fig. 19Table 13Summary of the fold increases in PKA activity.Table 13TreatmentFold increase in PKA activityForskolin (20 μM, 5 min)2.97 ± 0.24Dexamethasone (1nM, 5 min)1.9 ± 0.17Dexamethasone (1 nM, 5 min) + PD98059 (50 μM, 30 min prior treatment)1.68 ± 0.09Dexamethasone (1 nM, 5 min) + PTX (2 μg/l, 20 min prior treatment)1.18 ± 0.20Methanol (0.001% v/v, 5 min)1 ± 0

2.16. Activation of the ERK1/2 MAPK pathway by dexamethasone {#sec2.16}
------------------------------------------------------------

PKA is known to activate downstream ERK1/2 MAPK signaling to induce non-genomic responses to steroid hormones. The basal expression level of ERK1/2 MAPK in 16HBE14o^−^ cells was examined. Total untreated cellular lysates of 16HBE14o^−^ cells were prepared, subjected to western blot analysis and probed using a specific antibody recognising ERK1/2 MAPK. Expression differences were normalized for loading by probing for total β-actin levels. MCF-7 cells were used as a positive control as they are known to express ERK1/2 MAPK. This result clearly showed that ERK1/2 MAPK was expressed in 16HBE14o^−^ cells ([Fig. 20](#fig20){ref-type="fig"}).Fig. 20**ERK1/2 MAPK is expressed in 16HBE14o**^**−**^**cells. A:** The graph represents densitometric analysis of MAPK expression. Values are given as fold changes in ERK1/2 MAPK expression in MCF- 7 and 16HBE14o-cell lysates. Values are displayed as mean ± SEM (n = 3). Statistical analysis: Student\'s paired *t*-test. **B:** Representative Western blot analysis of ERK1/2 MAPK in cellular extracts of 16HBE14o- and MCF-7 cells. Total protein (30 μg/lane) was transferred to nitrocellulose membranes after fractionating by SDS-PAGE and blotted with anti-ERK1/2 MAPK. β-actin (42 kDa) was used as an internal control to estimate protein loading.Fig. 20

2.17. Dexamethasone activation of ERK1/2 MAPK {#sec2.17}
---------------------------------------------

The effect of dexamethasone on the activation of ERK1/2 MAPK was next examined. Phosphorylation of ERK1/2 MAPK on key threonine 202 and tyrosine 204 residues is strongly correlated with an increased activation of these kinases.

An antibody specific for phospho-ERK1/2 MAPK was used to determine phosphorylation in response to dexamethasone by western blot analysis. As shown in [Fig. 21](#fig21){ref-type="fig"}, dexamethasone (1 nM) produced a biphasic activation of ERK1/2 MAPK. ERK1/2 activation was observed as early as 2 minutes reaching a maximal activation at 10 minutes, thereafter returning to basal levels by 15 minutes. Dexamethasone treatment increased ERK1/2 MAPK phosphorylation levels compared to vehicle controls ([Table 14](#tbl14){ref-type="table"}). In 16HBE14o^−^ cells the rapid activation of ERK1/2 MAPK occurs in a time frame consistent with the rapid activation of PKA by dexamethasone.Fig. 21**ERK1/2 MAPK is rapidly activated in response to dexamethasone in 16HBE14o**^**−**^**cells. A:** The graph represents densitometric analysis at specific time points of dexamethasone treatment. Values are given as fold changes in ERK1/2 MAPK activation in 16HBE14o^−^ cell lysates. Values are displayed as mean ± SEM (n = 4). \*\* Denotes significance (p \< 0.001) between control and treated values. Statistical analysis was performed by one-way ANOVA followed by Tukey\'s multiple comparison tests. **B:** Representative western blot analysis of phospho-ERK1/2 MAPK in cellular extracts of 16HBE14o^−^. By employing antibodies specific to the phosphorylated form of ERK1/2 (Thr 202/Tyr 204), its activation by dexamethasone was monitored by Western blot analysis. Dexamethasone (1 nM) produced a biphasic activation of ERK1/2 that peaked at 2 and 10 minutes.Fig. 21Table 14Summary of the fold increases in ERK1/2 MAPK activity induced by dexamethasone.Table 14TreatmentFold increase in ERK1/2 MAPK activityLysate control1 ± 0Dexamethasone (1 nM, 2 min)3.08 ± 0.26Dexamethasone (1 nM, 5 min)2.17 ± 0.4Dexamethasone (1 nM, 10 min)5.83 ± 0.23Dexamethasone (1 nM, 15 min)1.6 ± 0.53Methanol (0.001% v/v, 2 min)0.85 ± 0.12Methanol (0.001% v/v, 5 min)0.93 ± 0.17Methanol (0.001% v/v, 10 min)0.89 ± 0.14Methanol (0.001% v/v, 15 min)1.6 ± 0.53

2.18. Non-genomic response - dexamethasone induces ERK1/2 MAPK activation independent of mRNA translation {#sec2.18}
---------------------------------------------------------------------------------------------------------

The time course (5 minutes) of the dexamethasone effect on ERK1/2 MAPK activity suggests that this response does not involve a classical genomic mechanism. In order to verify this hypothesis we tested the dexamethasone (1 nM) response in the presence of cycloheximide, an inhibitor of mRNA translation. As shown in [Fig. 22](#fig22){ref-type="fig"}, the increase in ERK1/2 MAPK activity following dexamethasone treatment was not reduced by preincubation with cycloheximide (1 μM) ([Table 15](#tbl15){ref-type="table"}). EGF (100 ng/mg) was used as a positive control for MAPK activation. These results indicate a mechanism of dexamethasone-induced activation of ERK1/2 MAPK that is independent of *de novo* protein synthesis.Fig. 22**Dexamethasone induces ERK1/2 MAPK activation independent mRNA translation. A:** The graph represents densitometric analysis at specific time points of dexamethasone treatment. Values are given as fold changes in ERK1/2 activation of 16HBE14o^−^ cell lysates. Values are displayed as mean ± SEM (n = 3); n.s. denotes not significant between dexamethasone and dexamethasone and inhibitor treated values. Statistical analysis was performed by one-way ANOVA followed by Tukey\'s multiple comparison tests. **B:** Representative Western blot analysis of phospho-ERK1/2 MAPK in cellular extracts of 16HBE14o^−^. The effect of inhibiting translation on the dexamethasone induced MAPK activation was determined by Western blot. Lane 1, lysate control, Lane 2, dexamethasone (1 nM, 5 min), Lane 3, Cycloheximide (prior treatment 1 μM/60 min) and dexamethasone (1 nM, 5 min), Lane 4, vehicle control (methanol, 0.001% v/v, 5 min), Lane 5, vehicle control (methanol 0.001% v/v, 5 min), Lane 6, EGF (100 ng/ml, 10 min).Fig. 22Table 15Summary of the fold increases in ERK1/2 MAPK activity induced by Dexa.Table 15TreatmentFold increase in ERK1/2 MAPK activityLysate control1 ± 0Dexamethasone (1 nM, 10 min)2.44 ± 0.53Dexamethasone (1 nM, 10 min) + cycloheximide (1 μM, 60 min prior treatment)2.17 ± 0.4Methanol (0.001% v/v, 10 min)1.21 ± 0.24Methanol (0.001% v/v, 10 min) + cycloheximide (1 μM)1.74 ± 0.32EGF (100 ng/ml, 10 min)4.54 ± 1.63

2.19. Dexamethasone PKA activation is upstream of MAPK activation {#sec2.19}
-----------------------------------------------------------------

The potential role of PKA in dexamethasone-induced activation of ERK 1/2 MAPK was examined. As shown in [Fig. 23](#fig23){ref-type="fig"}, dexamethasone (1 nM) stimulated ERK1/2 MAPK phosphorylation in 16HBE14o^--^ cells (p \< 0.001) (*lane 2*). The rapid activation of MAPK by dexamethasone was significantly inhibited (*p* \< 0.001) by the PKA inhibitor H89 (10 μM) (*lane 4*) demonstrating that PKA is activated upstream of ERK1/2 MAPK. As an internal control the MEK 1 inhibitor PD98059 (25 μM) (*lane 5*) inhibited the ERK1/2 MAPK activity. [Table 16](#tbl16){ref-type="table"} shows a summary of fold increases in ERK1/2 MAPK activity.Fig. 23**Effect of the PKA inhibitor, H89 and the MEK1 inhibitor, PD98059 on dexamethasone-induced ERK 1/2-activation. A:** The graph represents densitometric analysis at specific time points of dexamethasone treatment. Values are given as fold changes in ERK1/2 activation of 16HBE14o^−^ cell lysates. Values are displayed as mean ± SEM (n = 3); \*\* denotes values were significant (p \< 0.001) between dexamethasone and dexamethasone and inhibitor treated values. Statistical analysis was performed by one-way ANOVA followed by Tukey\'s multiple comparison tests. **B:** Representative Western blot analysis of phospho-ERK1/2 MAPK in cellular extracts of 16HBE14o^−^. 16HBE14o^−^ cells were treated with lysate control (Ctl) (*lane 1*), dexamethasone 1nM (*lane 2*), vehicle control (methanol, 0.001%) (*Lane 3*), dexamethasone (1 nM) after pretreatment with PD98059 (25 μM, 20 mins) (*lane 4*), dexamethasone (1 nM) after pretreatment with H89 (10 μM, 20 mins) (*lane 5*). Effect of methanol on inhibitor pre-treatment of PD98059 (*lane 6*) and H89 (*lane 7*).Fig. 23Table 16Summary of the fold increases in ERK1/2 MAPK activity.Table 16TreatmentFold increase in ERK1/2 MAPK activityLysate control1 ± 0Dexamethasone (1 nM, 10 min)4.0 ± 1.4Methanol (0.001% v/v, 10 min)1.4 ± 0.35Dexamethasone (1 nM, 10 min) + PD98059 (50 μM, 20 min pre-treatment)1.8 ± 0.7Dexamethasone (1 nM) + H89 (10 μM, 20 min pre-treatment)0.8 ± 0.20PD98059 (50 μM) + methanol (0.001% v/v)0.73 ± 0.26H89 (10 μM) + methanol (0.001% v/v)1.65 ± 0.36

2.20. PKC activation is upstream of PKA {#sec2.20}
---------------------------------------

The data indicate that dexamethasone induced MAP kinase activation is dependent on upstream PKA activity. What dexamethasone modulated kinase, if any, is upstream of PKA ?

In order to determine whether PKC activation was involved in the dexamethasone induced activation of PKA, the effects of the PKCα inhibitor 2,2′,3,3′,4,4′-Hexahydroxy-1,1′-biphenyl-6,6′-dimethanol Dimethyl Ether (HBDDE), a selective inhibitor of PKCα and PKCγ (IC~50~ concentration: PKCα, 43 μM and PKCγ 50 μM) was examined. PKCγ was not expressed in the human airway epithelial cells (it is exclusively expressed in brain and spinal tissue). Dexamethasone induced PKA activation was calculated as fold increases (arbitrary units, A.U.). Serum starved cells were treated with HBDDE (100 μM) for 30 mins before dexamethasone treatment (1 nM). Vehicle and HBDDE on its own had no effect on basal PKA activity. However, pretreatment with the PKCα inhibitor HBDDE (100 μM) prevented dexamethasone induced PKA activation ([Fig. 24](#fig24){ref-type="fig"}, [Table 17](#tbl17){ref-type="table"}). This result shows that PKA activated in response to dexamethasone is downstream of PKCα.Fig. 24**PKA activated in response to dexamethasone and is downstream of PKC**$\alpha$**.** The graph represents densitometric analysis of treatments. Values are given as fold changes in PKA activation measured as phosphorylation of the F-Kemptide PepTag for 16HBE14o^−^ cell lysates. Values are displayed as mean ± SEM (n = 3), \* denotes (p \> 0.01) between dexamethasone and dexamethasone plus PKC $\alpha$ inhibitor. Statistical analysis was performed by one-way ANOVA followed by Tukey\'s multiple comparison tests. UV-illuminated agarose gel of the products of reactions run with F-Kemptide and 16HBE14o^−^ homogenate. Lane 1, lysate control; Lane 2, dexamethasone (1 nM, 5 min); Lane 3, HBDDE (prior treatment 100 μM/40 min) and dexamethasone (1 nM, 5 min) Lane 4, vehicle control (methanol, 0.001% v/v, 5 min), Lane 5, methanol 0.001% v/v, 5 min and vehicle control (DMSO 0.1% v/v) for HBDDE.Fig. 24Table 17Summary of the fold increases in PKA activity.Table 17TreatmentFold increase in PKA activityLysate control1 ± 0Dexamethasone (1nM, 5 min)2.15 ± 0.12Dexamethasone (1 nM, 5 min) + HBDDE (100 μM, 30 min prior treatment)1.36 ± 0.18Methanol (0.001% v/v, 5 min)1.35 ± 0.08Methanol (0.001% v/v, 5 min) + HBDDE (100 μM, 30 min prior treatment)1.34 ± 0.05

2.21. Effect of dexamethasone on PKD1 activation in 16HBE14o^−^ cells {#sec2.21}
---------------------------------------------------------------------

Protein kinase D is a potential downstream target of cPKC and nPKCs. To determine whether dexamethasone stimulated activation of PKD1 in 16HBE14o^−^ cells, serum starved cells were treated with dexamethasone (1 nM) and PKD1 activity was assessed by probing with an antibody specific to phosphorylation to Ser916. Residue Ser916 is a site of autophosphorylation in the PKD1 structure that occurs subsequent to phosphorylation at Ser744/748 by PKC. Phosphorylation at Ser916 is therefore indicative of PKD activation. Treatment of 16HBE14o^−^ cells with dexamethasone had no significant effect on PKD1 phosphorylation levels ([Fig. 25](#fig25){ref-type="fig"}, [Table 18](#tbl18){ref-type="table"}). Bombesin was used as a positive control as it is known to activate PKD1.Fig. 25**Dexamethasone does not activate PKD1 in 16HBE14o**^**−**^**cells.** Representative western blot analysis of phospho-PKD1 in cellular extracts of 16HBE14o^−^. By employing antibodies specific to the phosphorylated form of PKD1 (Ser 916), the activation by dexamethasone was monitored by Western blot analysis. β-actin (42 kDa) was used as an internal control to estimate protein loading. The graph represents densitometric analysis at specific time points of dexamethasone treatment. Bombesin (BOM) was used as a positive control for PKD1 activity. Values are given as fold changes in PKCε activation of 16HBE14o^−^ cell lysates. Values are displayed as mean ± SEM (n = 3); n.s. denotes no significance between control and treated values. Statistical analysis was performed by one-way ANOVA followed by Tukey\'s multiple comparison tests.Fig. 25Table 18Summary of the fold increases in PKD activity.Table 18TreatmentPKD activation (phosphorylation at Ser 729)Lysate control2.27 ± 0.26Dexamethasone (1nM, 2 min)1.7 ± 0.27Dexamethasone (1nM, 5 min)1.64 ± 0.32Dexamethasone (1nM, 10 min)2.19 ± 0.32Dexamethasone (1nM, 15 min)1.78 ± 0.26Methanol (0.001% v/v, 2 min)1.96 ± 0.06Methanol (0.001% v/v, 5 min)1.13 ± 0.13Methanol (0.001% v/v, 10 min)2.11 ± 0.30Methanol (0.001% v/v, 15 min)1.92 ± 1.16Bombesin4.13 ± 0.31Control1.4 ± 0.29
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